We identified ATP1A2 as the key gene; its expression level was decreased in AAA samples compared with control samples, which was validated by immunostaining and Western blot in human AAA samples and an angiotensin II (Ang II)‐induced mouse model of AAA. Here, ATP1A2 is linked to triple-A syndrome.